Stereotaxis, Inc.

Zacks Investment Research•8/11/2026

Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates

Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.05 per share a year ago.

GlobeNewsWire•8/11/2026

Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates

GlobeNewsWire•7/21/2026

Stereotaxis to Report Second Quarter 2026 Financial Results on August 11, 2026

GlobeNewsWire•7/20/2026

University of Szeged Pioneers First Robotic Cardiology Program in Hungary

First Robotic Magnetic Navigation system installed in Hungary University of Szeged, led by Cardiology Chief Dr. Szili-Torok, expected to treat hundreds of patients annually with all forms of cardiac arrhythmia using precision of robotics ST. LOUIS, July 20, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of the first advanced robotic cardiology program in Hungary at the University of Szeged in Szeged, Hungary.

GlobeNewsWire•7/9/2026

Stereotaxis Completes Acquisition of Robocath

ST. LOUIS and ROUEN, France, July 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has completed its previously announced acquisition of Robocath, an innovator of robotic technologies for interventional cardiology and neurointerventions.